NKTR Description — Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s proprietary drugs and drug candidates that have either received regulatory approval or are being developed by Co. or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD™, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology.

Company Name: 
Nektar Therapeutics
Drugs & Pharmaceuticals
Number of ETFs Holding NKTR: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   NKTR Weight   NKTR Amount 
 IJH   0.21%   $102,193,244         
 VTI   0.01%   $99,291,829         
 VB   0.09%   $90,233,117         
 FBT   3.04%   $53,096,870         
 VBK   0.20%   $52,775,292         
 VXF   0.07%   $50,218,411         
 IBB   0.44%   $31,898,170         
 IJJ   0.30%   $17,413,689         
 XT   0.46%   $10,806,563         
 VHT   0.08%   $9,241,869         
List of all 48 ETFs holding NKTR »
Quotes delayed 20 minutes

Buy (2.89 out of 4)
33rd percentile
(ranked lower than approx. 67% of all stocks covered)

Analysts Forecast:
NKTR Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding NKTR | Nektar Therapeutics | ETF Channel |

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.